Russian company Biocad gains distribution rights for its rituximab and trastuzumab biosimilars in Bosnia and Herzegovina.
The Russian company Biocad received marketing approval for 2 biosimilars in Bosnia and Herzegovina, a country on the Balkan Peninsula in Southeastern Europe, and aims to expand sales further into Europe.
The registration for the biosimilars of rituximab and trastuzumab, Acellbia and Herticad, respectively, was granted by The Agency for Medicinal Products and Medical Devices of Bosnia and Herzegovina. Market launch, largely through individual contracts with state and private cancer centers, will start this year.
Biocad will produce the agents and distribution will be managed by ICM, according to a release. ICM estimated the market for rituximab and trastuzumab Bosnia and Herzegovina at around $12.7 million.
“The sale of these medicines on the market of Bosnia and Herzegovina will enable significant savings in the Federal Health Insurance Fund [FHIF] and at the same time enable patients to receive more effective treatment,” according to Nicola Rosič, chief executive officer of ICM, a distribution company based in Bosnia and Herzegovina.
“By analyzing international markets for launching drugs, we see that our products are in demand,” said Dmitry Morozov, chief executive officer of Biocad. “Therefore, in parallel, we conduct registration processes in different countries of Europe. For example, after successful registration in Bosnia and Herzegovina, we are planning to gain access to the Serbian market.”
Biocad’s Herticad has been approved for use in Russia and has been available since 2016.
The healthcare system in Bosnia and Herzegovina is known to be troubled by underfunding and a shortage of trained personnel caused in part by wartime exodus. The FHIF supervises the management of mandatory health insurance funds collected by the state healthcare system’s 10 health departments.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.